Sphingosine‐1‐phosphate signalling in the heart: exploring emerging perspectives in cardiopathology
FEBS Letters · 2024-11 · 598 (21) · 2641-2655
DOI: 10.1002/1873-3468.14973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift FEBS Letters, online erschienen am 04.07.2024. Verfasst von Franck Phan und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Lysophospholipids, Sphingosine, Signal Transduction, Heart Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche, Société Francophone du Diabète.
Abstract (Originalsprache)
Cardiometabolic disorders contribute to the global burden of cardiovascular diseases. Emerging sphingolipid metabolites like sphingosine‐1‐phosphate (S1P) and its receptors, S1PRs, present a dynamic signalling axis significantly impacting cardiac homeostasis. S1P's intricate mechanisms extend to its transportation in the bloodstream by two specific carriers: high‐density lipoprotein particles and albumin. This intricate transport system ensures the accessibility of S1P to distant target tissues, influencing several physiological processes critical for cardiovascular health. This review delves into the diverse functions of S1P and S1PRs in both physiological and pathophysiological conditions of the heart. Emphasis is placed on their diverse roles in modulating cardiac health, spanning from cardiac contractility, angiogenesis, inflammation, atherosclerosis and myocardial infarction. The intricate interplays involving S1P and its receptors are analysed concerning different cardiac cell types, shedding light on their respective roles in different heart diseases. We also review the therapeutic applications of targeting S1P/S1PRs in cardiac diseases, considering existing drugs like Fingolimod, as well as the prospects and challenges in developing novel therapies that selectively modulate S1PRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, Paris, France.
- Diabetology Department, Assistance Publique-Hôpitaux de Paris (APHP), La Pitié-Salpêtrière-Charles Foix University Hospital, Paris, France.
- Institut Hospitalo-Universitaire ICAN, Paris, France.
- Institut des Neurosciences Paris-Saclay, CNRS UMR 9197, Université Paris-Saclay, France.
ORCID-Profile: Eric Hajduch
Förderung
- Agence Nationale de la Recherche
- Société Francophone du Diabète
Zitieren
APA
Phan, F., Bourron, O., Foufelle, F., Le Stunff, H., & Hajduch, E. (2024). Sphingosine‐1‐phosphate signalling in the heart: exploring emerging perspectives in cardiopathology. FEBS Letters, 598(21), 2641-2655. https://doi.org/10.1002/1873-3468.14973
Vancouver
Phan F, Bourron O, Foufelle F, Le Stunff H, Hajduch E. Sphingosine‐1‐phosphate signalling in the heart: exploring emerging perspectives in cardiopathology. FEBS Letters. 2024;598(21):2641-2655. doi:10.1002/1873-3468.14973
BibTeX
@article{Phan2024,
author = {Phan, Franck and Bourron, Olivier and Foufelle, Fabienne and Le Stunff, Hervé and Hajduch, Eric},
title = {Sphingosine‐1‐phosphate signalling in the heart: exploring emerging perspectives in cardiopathology},
journal = {FEBS Letters},
year = {2024},
volume = {598},
number = {21},
pages = {2641--2655},
doi = {10.1002/1873-3468.14973}
}
EUVIMED